Key Insights
The Asia-Pacific nuclear medicine market is poised for significant expansion, driven by the increasing prevalence of chronic diseases, particularly cancer and cardiovascular conditions, necessitating advanced diagnostic solutions like PET scans. Technological innovations in radioisotope production and imaging technologies are enhancing diagnostic precision and therapeutic outcomes. Growing healthcare investments and heightened awareness of nuclear medicine applications, especially in emerging economies such as China and India, are key growth drivers. Government support for advanced healthcare infrastructure and R&D investments further fortify market expansion. Despite challenges from regulatory complexities and high procedural costs, the market demonstrates a strong positive outlook.
Asia-Pacific Nuclear Medicine Industry Market Size (In Billion)
Within the Asia-Pacific region, oncology remains the dominant application for nuclear medicine, attributed to the high incidence of cancer. Cardiology and neurology segments are also experiencing robust growth, influenced by an aging demographic and rising rates of neurological disorders. The diagnostics sector leads product-wise, emphasizing the critical role of PET imaging in early disease detection. Key market participants, including GE Healthcare, Siemens Healthineers, and Lantheus Medical Imaging, are actively pursuing growth through strategic collaborations, new product introductions, and technological innovation. The forecast period (2025-2033) projects sustained market growth, with an anticipated Compound Annual Growth Rate (CAGR) of 8%. The market size is projected to reach $7.03 billion by 2025, with continued expansion across all segments and countries within the Asia-Pacific region.
Asia-Pacific Nuclear Medicine Industry Company Market Share
Asia-Pacific Nuclear Medicine Industry Market Report: 2019-2033
This comprehensive report provides an in-depth analysis of the Asia-Pacific nuclear medicine industry, offering valuable insights for industry professionals, investors, and strategic planners. The study period covers 2019-2033, with a base year of 2025 and a forecast period of 2025-2033. The report utilizes rigorous research methodologies to deliver actionable intelligence, enabling informed decision-making in this rapidly evolving market estimated to be worth xx Million in 2025.
Asia-Pacific Nuclear Medicine Industry Market Structure & Innovation Trends
The Asia-Pacific nuclear medicine market exhibits a moderately concentrated structure, with key players like GE Healthcare, Cardinal Health Inc, Siemens Healthineers AG, Nordion Inc, NTP Radioisotopes, Lantheus Medical Imaging Inc, Bracco Diagnostic Inc, and Curium holding significant market share. Precise market share data for each company is unavailable, but the combined share of these players is estimated to be around 65% in 2025. Innovation is driven by advancements in PET imaging technologies, radiopharmaceutical development, and the increasing demand for personalized medicine. Regulatory frameworks vary across the region, posing both opportunities and challenges. M&A activity is relatively high, with deal values averaging around xx Million in recent years, reflecting the strategic importance of this sector. For instance, the recent expansion of partnerships in clinical trials highlights collaborative efforts to accelerate innovation. Substitutes for nuclear medicine are limited, bolstering the market’s growth trajectory. End-user demographics are primarily hospitals and specialized clinics, with a growing contribution from private diagnostic centers.
Asia-Pacific Nuclear Medicine Industry Market Dynamics & Trends
The Asia-Pacific nuclear medicine market is experiencing robust growth, driven by several factors. Rising prevalence of chronic diseases like cancer and cardiovascular ailments fuels the demand for diagnostic and therapeutic nuclear medicine procedures. Technological advancements, particularly in PET/CT and SPECT/CT imaging systems, are enhancing diagnostic accuracy and treatment efficacy. Government initiatives promoting healthcare infrastructure development across the region provide favorable market conditions. A CAGR of approximately 8% is projected for the period 2025-2033, largely driven by increased access to healthcare and adoption of advanced imaging technologies. The market penetration of advanced imaging techniques like PET scans is still relatively low in some countries, representing a significant opportunity for growth. Competitive dynamics are characterized by both collaboration and competition among major players.
Dominant Regions & Segments in Asia-Pacific Nuclear Medicine Industry
Dominant Region: Japan and China lead the Asia-Pacific nuclear medicine market due to their advanced healthcare infrastructure, high prevalence of target diseases, and substantial government investment in healthcare. India's growing healthcare sector also contributes significantly.
Dominant Segments:
- By Application: Oncology remains the largest segment due to the high incidence of cancer in the region. Cardiology and Neurology segments are also experiencing significant growth, driven by increasing prevalence of cardiovascular and neurological disorders.
- By Product: Diagnostics holds a larger market share compared to therapeutics currently, primarily due to the widespread availability of diagnostic imaging technologies. However, the therapeutics segment is expected to witness faster growth, fueled by advancements in targeted radionuclide therapies.
- Positron Emission Tomography (PET): PET imaging is witnessing considerable growth in the region, attributable to its improved accuracy and utility in early cancer detection. Therapeutic applications using PET-guided treatments are also gaining traction.
Key drivers for these dominant segments include favorable government policies supporting healthcare infrastructure and technological advancements in imaging and therapy. The increasing awareness of the benefits of early disease detection and advanced treatment options also contributes to the market growth.
Asia-Pacific Nuclear Medicine Industry Product Innovations
Recent product innovations focus on enhancing image resolution, improving patient comfort, and expanding therapeutic applications. Miniaturized PET scanners and novel radiopharmaceuticals are gaining traction. These advancements address unmet needs and offer competitive advantages by enhancing diagnostic accuracy and treatment efficacy. The market trend favors integrated imaging systems that combine PET/CT or SPECT/CT functionalities, delivering comprehensive diagnostic information in a single session.
Report Scope & Segmentation Analysis
This report segments the Asia-Pacific nuclear medicine market by product (Diagnostics and Therapeutics), application (Cardiology, Neurology, Oncology, Other Applications), and technology (PET, SPECT, other). Each segment offers detailed growth projections and competitive landscapes. For example, the oncology application segment is expected to witness the highest CAGR due to the rising prevalence of cancer. The PET technology segment is projected to grow rapidly, driven by its superior imaging capabilities. Competitive intensity varies across segments and regions.
Key Drivers of Asia-Pacific Nuclear Medicine Industry Growth
The Asia-Pacific nuclear medicine market is propelled by several factors. The rising prevalence of chronic diseases like cancer, cardiovascular, and neurological disorders significantly fuels demand. Technological advancements, such as improved imaging systems and targeted therapies, enhance treatment efficacy and early diagnosis. Increasing government investments in healthcare infrastructure across several countries create conducive market conditions, further boosting adoption. Government initiatives promoting early disease screening and promoting healthcare awareness increase access and utilization of nuclear medicine procedures.
Challenges in the Asia-Pacific Nuclear Medicine Industry Sector
Challenges include regulatory complexities in various countries, stringent safety standards, and the high cost of advanced equipment. Supply chain disruptions can impact the availability of radioisotopes and imaging equipment. Furthermore, intense competition among established players and emerging companies necessitates continuous innovation and strategic adaptation. These challenges, if not adequately addressed, could impact the market's projected growth rate.
Emerging Opportunities in Asia-Pacific Nuclear Medicine Industry
Emerging opportunities lie in the expanding use of theranostics (combination of diagnosis and therapy), personalized medicine approaches, and the development of novel radiopharmaceuticals. The growing focus on preventive healthcare and early disease detection will further stimulate demand. Expansion into untapped markets in developing economies presents significant potential for growth. The adoption of telemedicine and remote diagnostics also offers new avenues for market expansion.
Leading Players in the Asia-Pacific Nuclear Medicine Industry Market
- Nordion Inc
- GE Healthcare
- Cardinal Health Inc
- Siemens Healthineers AG
- NTP Radioisotopes
- Lantheus Medical Imaging Inc
- Bracco Diagnostic Inc
- Curium
Key Developments in Asia-Pacific Nuclear Medicine Industry Industry
- May 2022: Ion Beam Applications S.A. received an order for a Proteus PLUS proton therapy system from CGN Medical Technologies for installation in Yangzhou, China. This signifies growing investment in advanced cancer therapies within the region.
- January 2022: Clario and XingImaging expanded their partnership to deliver PET imaging clinical trials for novel therapeutics in China. This highlights the increasing role of clinical trials in driving innovation and adoption of new therapies.
Future Outlook for Asia-Pacific Nuclear Medicine Industry Market
The Asia-Pacific nuclear medicine market exhibits a promising outlook, fueled by continuous technological advancements, rising healthcare expenditure, and increasing disease prevalence. Strategic partnerships, product innovation, and expansion into untapped markets will be key to realizing the full potential of this rapidly evolving sector. The integration of AI and machine learning in diagnostic imaging is expected to further transform the market landscape.
Asia-Pacific Nuclear Medicine Industry Segmentation
-
1. Product
-
1.1. Diagnostics
- 1.1.1. Single Photon Emission Computed Tomography (SPECT)
- 1.1.2. Positron Emission Tomography (PET)
-
1.2. Therapeutics
- 1.2.1. Alpha Emitters
- 1.2.2. Beta Emitters
- 1.2.3. Brachytherapy
-
1.1. Diagnostics
-
2. Application
- 2.1. Cardiology
- 2.2. Neurology
- 2.3. Oncology
- 2.4. Other Applications
-
3. Geography
- 3.1. China
- 3.2. Japan
- 3.3. India
- 3.4. Australia
- 3.5. South Korea
- 3.6. Rest of Asia-Pacific
Asia-Pacific Nuclear Medicine Industry Segmentation By Geography
- 1. China
- 2. Japan
- 3. India
- 4. Australia
- 5. South Korea
- 6. Rest of Asia Pacific
Asia-Pacific Nuclear Medicine Industry Regional Market Share
Geographic Coverage of Asia-Pacific Nuclear Medicine Industry
Asia-Pacific Nuclear Medicine Industry REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2020-2034 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Historical Period | 2020-2025 |
| Growth Rate | CAGR of 8% from 2020-2034 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Rise in Prevalence of Cancer and Cardiac Disorders; Increasing Demand for Biosimilar Drugs Due to Their Cost Effectiveness
- 3.3. Market Restrains
- 3.3.1. High Cost of the Diagnostic and Therapeutic Equipment and Procedures; Regulatory Uncertainty
- 3.4. Market Trends
- 3.4.1. Oncology Segment Expects to Register a High CAGR in the Asia-Pacific Nuclear Medicine Market Over the Forecast Period
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Asia-Pacific Nuclear Medicine Industry Analysis, Insights and Forecast, 2020-2032
- 5.1. Market Analysis, Insights and Forecast - by Product
- 5.1.1. Diagnostics
- 5.1.1.1. Single Photon Emission Computed Tomography (SPECT)
- 5.1.1.2. Positron Emission Tomography (PET)
- 5.1.2. Therapeutics
- 5.1.2.1. Alpha Emitters
- 5.1.2.2. Beta Emitters
- 5.1.2.3. Brachytherapy
- 5.1.1. Diagnostics
- 5.2. Market Analysis, Insights and Forecast - by Application
- 5.2.1. Cardiology
- 5.2.2. Neurology
- 5.2.3. Oncology
- 5.2.4. Other Applications
- 5.3. Market Analysis, Insights and Forecast - by Geography
- 5.3.1. China
- 5.3.2. Japan
- 5.3.3. India
- 5.3.4. Australia
- 5.3.5. South Korea
- 5.3.6. Rest of Asia-Pacific
- 5.4. Market Analysis, Insights and Forecast - by Region
- 5.4.1. China
- 5.4.2. Japan
- 5.4.3. India
- 5.4.4. Australia
- 5.4.5. South Korea
- 5.4.6. Rest of Asia Pacific
- 5.1. Market Analysis, Insights and Forecast - by Product
- 6. China Asia-Pacific Nuclear Medicine Industry Analysis, Insights and Forecast, 2020-2032
- 6.1. Market Analysis, Insights and Forecast - by Product
- 6.1.1. Diagnostics
- 6.1.1.1. Single Photon Emission Computed Tomography (SPECT)
- 6.1.1.2. Positron Emission Tomography (PET)
- 6.1.2. Therapeutics
- 6.1.2.1. Alpha Emitters
- 6.1.2.2. Beta Emitters
- 6.1.2.3. Brachytherapy
- 6.1.1. Diagnostics
- 6.2. Market Analysis, Insights and Forecast - by Application
- 6.2.1. Cardiology
- 6.2.2. Neurology
- 6.2.3. Oncology
- 6.2.4. Other Applications
- 6.3. Market Analysis, Insights and Forecast - by Geography
- 6.3.1. China
- 6.3.2. Japan
- 6.3.3. India
- 6.3.4. Australia
- 6.3.5. South Korea
- 6.3.6. Rest of Asia-Pacific
- 6.1. Market Analysis, Insights and Forecast - by Product
- 7. Japan Asia-Pacific Nuclear Medicine Industry Analysis, Insights and Forecast, 2020-2032
- 7.1. Market Analysis, Insights and Forecast - by Product
- 7.1.1. Diagnostics
- 7.1.1.1. Single Photon Emission Computed Tomography (SPECT)
- 7.1.1.2. Positron Emission Tomography (PET)
- 7.1.2. Therapeutics
- 7.1.2.1. Alpha Emitters
- 7.1.2.2. Beta Emitters
- 7.1.2.3. Brachytherapy
- 7.1.1. Diagnostics
- 7.2. Market Analysis, Insights and Forecast - by Application
- 7.2.1. Cardiology
- 7.2.2. Neurology
- 7.2.3. Oncology
- 7.2.4. Other Applications
- 7.3. Market Analysis, Insights and Forecast - by Geography
- 7.3.1. China
- 7.3.2. Japan
- 7.3.3. India
- 7.3.4. Australia
- 7.3.5. South Korea
- 7.3.6. Rest of Asia-Pacific
- 7.1. Market Analysis, Insights and Forecast - by Product
- 8. India Asia-Pacific Nuclear Medicine Industry Analysis, Insights and Forecast, 2020-2032
- 8.1. Market Analysis, Insights and Forecast - by Product
- 8.1.1. Diagnostics
- 8.1.1.1. Single Photon Emission Computed Tomography (SPECT)
- 8.1.1.2. Positron Emission Tomography (PET)
- 8.1.2. Therapeutics
- 8.1.2.1. Alpha Emitters
- 8.1.2.2. Beta Emitters
- 8.1.2.3. Brachytherapy
- 8.1.1. Diagnostics
- 8.2. Market Analysis, Insights and Forecast - by Application
- 8.2.1. Cardiology
- 8.2.2. Neurology
- 8.2.3. Oncology
- 8.2.4. Other Applications
- 8.3. Market Analysis, Insights and Forecast - by Geography
- 8.3.1. China
- 8.3.2. Japan
- 8.3.3. India
- 8.3.4. Australia
- 8.3.5. South Korea
- 8.3.6. Rest of Asia-Pacific
- 8.1. Market Analysis, Insights and Forecast - by Product
- 9. Australia Asia-Pacific Nuclear Medicine Industry Analysis, Insights and Forecast, 2020-2032
- 9.1. Market Analysis, Insights and Forecast - by Product
- 9.1.1. Diagnostics
- 9.1.1.1. Single Photon Emission Computed Tomography (SPECT)
- 9.1.1.2. Positron Emission Tomography (PET)
- 9.1.2. Therapeutics
- 9.1.2.1. Alpha Emitters
- 9.1.2.2. Beta Emitters
- 9.1.2.3. Brachytherapy
- 9.1.1. Diagnostics
- 9.2. Market Analysis, Insights and Forecast - by Application
- 9.2.1. Cardiology
- 9.2.2. Neurology
- 9.2.3. Oncology
- 9.2.4. Other Applications
- 9.3. Market Analysis, Insights and Forecast - by Geography
- 9.3.1. China
- 9.3.2. Japan
- 9.3.3. India
- 9.3.4. Australia
- 9.3.5. South Korea
- 9.3.6. Rest of Asia-Pacific
- 9.1. Market Analysis, Insights and Forecast - by Product
- 10. South Korea Asia-Pacific Nuclear Medicine Industry Analysis, Insights and Forecast, 2020-2032
- 10.1. Market Analysis, Insights and Forecast - by Product
- 10.1.1. Diagnostics
- 10.1.1.1. Single Photon Emission Computed Tomography (SPECT)
- 10.1.1.2. Positron Emission Tomography (PET)
- 10.1.2. Therapeutics
- 10.1.2.1. Alpha Emitters
- 10.1.2.2. Beta Emitters
- 10.1.2.3. Brachytherapy
- 10.1.1. Diagnostics
- 10.2. Market Analysis, Insights and Forecast - by Application
- 10.2.1. Cardiology
- 10.2.2. Neurology
- 10.2.3. Oncology
- 10.2.4. Other Applications
- 10.3. Market Analysis, Insights and Forecast - by Geography
- 10.3.1. China
- 10.3.2. Japan
- 10.3.3. India
- 10.3.4. Australia
- 10.3.5. South Korea
- 10.3.6. Rest of Asia-Pacific
- 10.1. Market Analysis, Insights and Forecast - by Product
- 11. Rest of Asia Pacific Asia-Pacific Nuclear Medicine Industry Analysis, Insights and Forecast, 2020-2032
- 11.1. Market Analysis, Insights and Forecast - by Product
- 11.1.1. Diagnostics
- 11.1.1.1. Single Photon Emission Computed Tomography (SPECT)
- 11.1.1.2. Positron Emission Tomography (PET)
- 11.1.2. Therapeutics
- 11.1.2.1. Alpha Emitters
- 11.1.2.2. Beta Emitters
- 11.1.2.3. Brachytherapy
- 11.1.1. Diagnostics
- 11.2. Market Analysis, Insights and Forecast - by Application
- 11.2.1. Cardiology
- 11.2.2. Neurology
- 11.2.3. Oncology
- 11.2.4. Other Applications
- 11.3. Market Analysis, Insights and Forecast - by Geography
- 11.3.1. China
- 11.3.2. Japan
- 11.3.3. India
- 11.3.4. Australia
- 11.3.5. South Korea
- 11.3.6. Rest of Asia-Pacific
- 11.1. Market Analysis, Insights and Forecast - by Product
- 12. Competitive Analysis
- 12.1. Market Share Analysis 2025
- 12.2. Company Profiles
- 12.2.1 Nordion Inc
- 12.2.1.1. Overview
- 12.2.1.2. Products
- 12.2.1.3. SWOT Analysis
- 12.2.1.4. Recent Developments
- 12.2.1.5. Financials (Based on Availability)
- 12.2.2 GE Healthcare
- 12.2.2.1. Overview
- 12.2.2.2. Products
- 12.2.2.3. SWOT Analysis
- 12.2.2.4. Recent Developments
- 12.2.2.5. Financials (Based on Availability)
- 12.2.3 Cardinal Health Inc
- 12.2.3.1. Overview
- 12.2.3.2. Products
- 12.2.3.3. SWOT Analysis
- 12.2.3.4. Recent Developments
- 12.2.3.5. Financials (Based on Availability)
- 12.2.4 Siemens Healthineers AG
- 12.2.4.1. Overview
- 12.2.4.2. Products
- 12.2.4.3. SWOT Analysis
- 12.2.4.4. Recent Developments
- 12.2.4.5. Financials (Based on Availability)
- 12.2.5 NTP Radioisotopes
- 12.2.5.1. Overview
- 12.2.5.2. Products
- 12.2.5.3. SWOT Analysis
- 12.2.5.4. Recent Developments
- 12.2.5.5. Financials (Based on Availability)
- 12.2.6 Lantheus Medical Imaging Inc
- 12.2.6.1. Overview
- 12.2.6.2. Products
- 12.2.6.3. SWOT Analysis
- 12.2.6.4. Recent Developments
- 12.2.6.5. Financials (Based on Availability)
- 12.2.7 Bracco Diagnostic Inc
- 12.2.7.1. Overview
- 12.2.7.2. Products
- 12.2.7.3. SWOT Analysis
- 12.2.7.4. Recent Developments
- 12.2.7.5. Financials (Based on Availability)
- 12.2.8 Curium
- 12.2.8.1. Overview
- 12.2.8.2. Products
- 12.2.8.3. SWOT Analysis
- 12.2.8.4. Recent Developments
- 12.2.8.5. Financials (Based on Availability)
- 12.2.1 Nordion Inc
List of Figures
- Figure 1: Asia-Pacific Nuclear Medicine Industry Revenue Breakdown (billion, %) by Product 2025 & 2033
- Figure 2: Asia-Pacific Nuclear Medicine Industry Share (%) by Company 2025
List of Tables
- Table 1: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Product 2020 & 2033
- Table 2: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Application 2020 & 2033
- Table 3: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Geography 2020 & 2033
- Table 4: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Region 2020 & 2033
- Table 5: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Product 2020 & 2033
- Table 6: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Application 2020 & 2033
- Table 7: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Geography 2020 & 2033
- Table 8: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Country 2020 & 2033
- Table 9: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Product 2020 & 2033
- Table 10: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Application 2020 & 2033
- Table 11: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Geography 2020 & 2033
- Table 12: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Country 2020 & 2033
- Table 13: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Product 2020 & 2033
- Table 14: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Application 2020 & 2033
- Table 15: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Geography 2020 & 2033
- Table 16: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Country 2020 & 2033
- Table 17: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Product 2020 & 2033
- Table 18: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Application 2020 & 2033
- Table 19: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Geography 2020 & 2033
- Table 20: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Country 2020 & 2033
- Table 21: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Product 2020 & 2033
- Table 22: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Application 2020 & 2033
- Table 23: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Geography 2020 & 2033
- Table 24: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Country 2020 & 2033
- Table 25: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Product 2020 & 2033
- Table 26: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Application 2020 & 2033
- Table 27: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Geography 2020 & 2033
- Table 28: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Country 2020 & 2033
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the Asia-Pacific Nuclear Medicine Industry?
The projected CAGR is approximately 8%.
2. Which companies are prominent players in the Asia-Pacific Nuclear Medicine Industry?
Key companies in the market include Nordion Inc, GE Healthcare, Cardinal Health Inc, Siemens Healthineers AG, NTP Radioisotopes, Lantheus Medical Imaging Inc, Bracco Diagnostic Inc, Curium.
3. What are the main segments of the Asia-Pacific Nuclear Medicine Industry?
The market segments include Product, Application, Geography.
4. Can you provide details about the market size?
The market size is estimated to be USD 7.03 billion as of 2022.
5. What are some drivers contributing to market growth?
Rise in Prevalence of Cancer and Cardiac Disorders; Increasing Demand for Biosimilar Drugs Due to Their Cost Effectiveness.
6. What are the notable trends driving market growth?
Oncology Segment Expects to Register a High CAGR in the Asia-Pacific Nuclear Medicine Market Over the Forecast Period.
7. Are there any restraints impacting market growth?
High Cost of the Diagnostic and Therapeutic Equipment and Procedures; Regulatory Uncertainty.
8. Can you provide examples of recent developments in the market?
In May 2022, Ion Beam Applications S.A. received an order from CGN Medical Technologies for a Proteus PLUS proton therapy system to be installed in Yangzhou, China.
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4750, USD 5250, and USD 8750 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in billion.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Asia-Pacific Nuclear Medicine Industry," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Asia-Pacific Nuclear Medicine Industry report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Asia-Pacific Nuclear Medicine Industry?
To stay informed about further developments, trends, and reports in the Asia-Pacific Nuclear Medicine Industry, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence